Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer

Lignende værker

• Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
  af: Huang, Ou, et al.
  Udgivet: (2009)
• Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
  af: Serin, D, et al.
  Udgivet: (2005)
• Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
  af: Pétain, Aurélie, et al.
  Udgivet: (2019)
• Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
  af: Zhang, Qingyuan, et al.
  Udgivet: (2016)
• A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer
  af: Yang, Yunpeng, et al.
  Udgivet: (2019)